Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
NPPA ORDER -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each hard gelatin capsule contains
1 Atorvastatin+ Clopidogrel+ Asprin Capsule
Atorvastatin Calcium eq to. Atorvastatin-10 mg (as film coated Tablet colour : Ponceau 4R & Red oxide of Iron) Clopidogrel bisulfate eq. to Clopidogrel-75 mg Asprin -75 mg (As enteric Coated Tablet Colour : Titanium Dioxide & Sunset Yellow FCF
10’s Strip/ Blister
34.42 37.89
*Subject to actual payment of Government levies/taxes, as applicable. NOTE: (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
…/2
-2- (i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.298(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each trilayer tablet contains
1 Metformin + Glilpizide + Pioglitazone Tablet
Metformin Hydrocloride-500mg (As Sustained Release) Glipizide-5 mg (As Sustained Release) Pioglitazone Hydrocloride eq to Pioglitazone 15 mg
10’s Strip/ Blister
23.56 25.94
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms claimed,
the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
…/3
-3- (f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.299(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each geletin coated tablet (soflet) contains 1 Metronidazole
Tablet Metronidazole-200 mg 15’s Strip/
Blister 14.24 15.68
2 Metronidazole
Tablet Metronidazole-400 mg 15’s Strip/
Blister 17.94 19.75
*Subject to actual payment of Government levies/taxes, as applicable. NOTE: (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
…/4
-4- (b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.300(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 897(E), dated 5th June, 2007, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/5
-5-
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each coated tablet contains
1 Sulphasalazine Tablet
Sulphasalazine-500 mg (Salazosulphapyradine)
10’s Strip/ Blister
34.96 38.49
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.301(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II
…/6
-6- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1641(E), dated 27th September, 2007, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each chewable tablet contains 1 Ascorbic acid+
Sodium Ascorbate Tablets
Ascorbic acid 100mg Sodium Ascorbate 450mg eq. to 400mg of Ascorbic acid
15’s Strip/ Blister
13.92 15.32
Each tablet contains
2 Vitamin C Tablets Vitamin C-500 mg 10’s Strip/ Blister
7.18 7.90
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
…/7
-7- (i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.302(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1638(E), dated 27th September, 2007 and S.O. 2027(E), dated 30th November, 2007, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains
1 Oxytetracycline+ Lidocaine Injections
Oxytetracycline eq. to anhydrous Oxytetracycline-50mg Lidocaine - 2% w/v
20 ml Vial 12.34 13.59
2 Oxytetracycline
Injections Oxytetracycline HCl-50mg 30 ml Vial 14.22 15.65
3 Oxytetracycline
Injections Oxytetracycline HCl-50mg 100 ml Vial 33.54 36.92
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
…/8
-8- (e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.303(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1054(E), dated 11th July, 2006, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each tablet contains
1 Trimethoprim+ Sulphamethoxazole Tablets
Trimethoprim 160 mg Sulphamethoxazole-800 mg
10’s Strip/Blister
11.22 12.35
*Subject to actual payment of Government levies/taxes, as applicable. …/9
-9- NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.304(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 174(E), dated 29th January, 2008 and S.O. 1958(E), dated 6th August, 2008, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/10
-10-
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each Soft Gelatin Capsule Contains 1 Ibuprofen+
Tizanidine Capsule
Ibuprofen - 400 mg Tizanidine HCL - 2.288 mg (eq. to Tizanidine Base - 2 mg)
10’s Strip/ Blister
15.42 16.98
Each film coated tablet contains
2 Ibuprofen Tablets
Ibuprofen -200 mg 10’s Strip/ Blister
3.40 3.74 3 Ibuprofen
Tablets Ibuprofen -400 mg 10’s Strip/
Blister 5.93 6.53
4 Ibuprofen
Tablets Ibuprofen -600 mg 10’s Strip/
Blister 8.52 9.38
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.305(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II
…/11
-11- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 440(E) & 441(E), dated 29th March, 2006, S.O. 772(E), dated 28th March, 2008, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each combi pack 2 Tab/cap contains 1 Rifampicin+
Isoniazide+ Ethambutol in a Fixed/dose combi pack
1 cap of Rifampicin-450 mg 1 tablet of Ethambutol-800 mg Isoniazid-300 mg
2’s Tab/Cap Combi Pack
Al/PVDC-PVC Blister
7.04 7.75
Each combi pack 4 Tab/cap contains 2 Rifampicin+
Isoniazide+ Pyrazinamide+ Ethambutol in a Fixed/dose combi pack
1 cap of Rifampicin-450 mg 1 tablet of Ethambutol-800 mg Isoniazid-300 mg 2 Tablet Contains Pyrazinamide - 750 mg
4’s Tab/Cap Combi Pack
Al/PVDC-PVC Blister
10.06 11.08
Each film coated tablet
Contains
3 Rifampicin+
Isoniazide+ Pyrazinamide+ Ethambutol Tablets
Rifampicin-150 mg Isoniazid-100 mg Pyrazinamide-500 mg Ethambutol HCL 267 mg
3’s Strip/ Blister
10.74 11.82
4 Rifampicin+
Isoniazide+ Ethambutol Tablets
Rifampicin-150 mg Isoniazid-75 mg Ethambutol HCL 275 mg
6’s Strip/ Blister
15.28 16.82
5 Rifampicin+
Isoniazide+ Pyrazianamide + Ethambutol Tablets
Rifampicin-150 mg Isoniazid-75 mg Pyrazianamide 400 mg Ethambutol HCL 275 mg
6’s Strip/ Blister
20.06 22.08
6 Rifampicin+
Isoniazide+ Ethambutol Tablets
Rifampicin-450 mg Isoniazid-300 mg Ethambutol HCL 800 mg
6’s Strip/ Blister
40.06 44.10
7 Rifampicin+
Isoniazide+ Pyrazianamide + Ethambutol Tablets
Rifampicin-225 mg Isoniazid-150 mg Pyrazianamide 750 mg Ethambutol HCL 400 mg
10’s Strip/ Blister
29.72 32.72
*Subject to actual payment of Government levies/taxes, as applicable.
…/12
-12- NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.306(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 2032(E), dated 30th November, 2007, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/13
-13-
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each tablet contains 1 Sulphadoxine+
Pyrimethamine Tablets Sulphadoxine - 500 mg Pyrimethamine - 25 mg
2’s Strip/ Blister
3.52 3.88
2 Sulphadoxine+
Pyrimethamine Tablets Sulphadoxine - 750 mg Pyrimethamine-37.5 mg
2’s Strip/ Blister
4.90 5.39
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.307(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II
…/14
-14- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 199(E), dated 14th February, 2007, No. S.O. 1319(E), dated 5th June, 2008 and No. S.O. 1991(E), dated 6th August, 2008, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each tablet contains 1 Analgin Tablet Analgin (Metamizole)-500mg 10’s Strip/Blister 7.28 8.01 Each ml contains 2 Analgin Injection Analgin (Metamizole)-0.5gm 2ml Amber Glass
Ampoules 4.42 4.87
3 Analgin+Chlorbu
tol Injection Analgin (Metamizole)-0.5gm Chlorbutol as Bacteriostatic - 0.4% w/v
30ml Amber Glass Vial
28.16 31.00
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
…/15
-15- (j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.308(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 430(E), dated 23rd March, 2007, S.O. 767(E), dated 28th March, 2008 and S.O. 1333(E), dated 5th June, 2008, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Chloroquine
Injections Chloroquine Phosphate-64.5mg eq. to 40 mg Chloroquine base Benzyl Alcohol (as preservative 2%v/v)
30ml Amber Vial
17.14 17.83
2 Chloroquine
Injections Chloroquine Phosphate-64.5mg eq. to 40 mg Chloroquine base
10x2 ml Amber Ampoule
35.08 36.48
3 Chloroquine
Injections Chloroquine Phosphate-64.5mg eq. to 40 mg Chloroquine base
5x5 ml Amber Ampoule
26.26 27.31
Each film coated tablet contains 4 Chloroquine
Tablets Chloroquine Phosphate-250mg 10’s Strip/
Blister 6.12 6.36
5 Chloroquine
Tablets Chloroquine Phosphate-500mg 5’s Strip/
Blister 5.88 6.12
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. …/16
-16- (d) For different packing material used or, different drug delivery systems or any other special features/ forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.309(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 744(E), dated 19th May, 2006, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Lincomycin
Injection Lincomycin HCl eq. to Lincomycin base - 300 mg
1ml Amber Ampoule
5.08 5.59
2 Lincomycin
Injection Lincomycin HCl eq. to Lincomycin base - 300 mg
2ml Amber Ampoule
8.42 9.27
*Subject to actual payment of Government levies/taxes, as applicable. …/17
-17- NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.310(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1961(E), dated 6th August, 2008 and No. S.O. 2059(E), dated 18th August, 2008, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/18
-18-
TABLE
Sl. No.
Name of the Formulation Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each tablet contains 1 Tablets of Ibuprofen +
Paracetamol & Others Ibuprofen - 400 mg Paracetamol - 325 mg
10’s Strip/ Blister
7.32 8.06
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) For all the other tablet formulations containing Ibuprofen + Paracetamol with or without other active ingredients
having composition different from contents mentioned in Column (3) of the above table, the following adjustment shall be made by a manufacturer to work out the maximum retail price (MRP) for a product under the said order for formulation (s) in column No. 2, when there is a change in the composition and the following factors (which are inclusive of admissible MAPE) shall be added/ subtracted as the case may be to the notified ceiling price given in column No. 5 of the table on the following basis:
For each 10 tablets in strip/blister:
1. For each 10 mg or part thereof of Ibuprofen Rs. 0.102 shall be added/subtracted. 2. For each 10 mg or part thereof of Paracetamol Rs. 0.04208 shall be added/subtracted. 3. For each 10 mg or part thereof of Caffeine (Any) Rs. 0.0921 shall be added/subtracted. 4. For each 10 mg or part thereof of Magnesium Trisilicate Rs. 0.0089 shall be added/subtracted. 5. For each 5 mg or part thereof of Pseudoephedrine HCL Rs. 0.1988 shall be added/subtracted. 6. For each 1 mg or part thereof of Chlorpheniramine Maleate Rs. 0.0135 shall be added/subtracted. 7. For each 10 mg or part thereof of Chlorzoxazone Rs. 0.1187 shall be added/subtracted. 8. For each 10 mg or part thereof of Methacarbamol Rs. 0.1074 shall be added/subtracted. 9. For each 5 mg or part thereof of Dextropropoxyphene HCL Rs. 0.4080 shall be added/subtracted. 10. For each 10 mg or part thereof of Diclofenac Pottasium/Sodium Rs. 0.1126 shall be added/subtracted. 11. For each 1 mg or part thereof of Codeine Phosphate Rs. 0.7306 shall be added/subtracted. 12. For each 5 mg or part thereof of Baralgen Ketone Rs. 0.2721 shall be added/subtracted. 13. For each 0.1 mg or part thereof of Baralgen Amide Rs. 0.0435 shall be added/subtracted. 14. For each 1 mg or part thereof of Serratiopeptidose Rs. 0.2989 shall be added/subtracted (b) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
…/19
-19- (h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.311(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each capsule contains 1 Cloxacillin+
Amoxycillin+ Serratiopeptidase Capsules
Cloxacillin Sodium - 250 mg Amoxycillin - 250 mg Serratiopeptidase - 10 mg
10’s Strip/ Blister
22.92 25.23
Each hard gelatin capsule contains
2 Cloxacillin+ Ampicillin Capsule
Cloxacillin Sodium eq. to Cloxacillin - 250 mg Ampicillin Trihydrate eq. to Ampicillin - 250 mg
10’s Strip/ Blister
17.86 19.66
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
…/20
-20- (c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms claimed,
the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.312(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Gentamycin+
Diclofenac Sodium+ Benzalkonium Chloride Eye Drops
Gentamycin Sulphate eq. to Gentamycin - 3 mg Diclofenac Sodium - 1 mg Benzalkonium Chloride Solution - 0.01% w/v
5 ml Vial with
Dropper & Carton
7.78 8.57
*Subject to actual payment of Government levies/taxes, as applicable. …/21
-21- NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.313(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/22
-22-
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Dexamethasone+
Polymixin B Sulphate+ Chloramphenicol+ Phenylmercuric Nitrate Eye/Ear Drops
Dexamethasone Sodium Phosphate - 1 mg Polymixin B Sulphate-5000IU Chloramphenicol - 4 mg Phenylmercuric Nitrate - 0.001%
5 ml Vial with
Dropper & Carton
10.26 11.30
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms claimed,
the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.314(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II
…/23
-23- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each tablet contains 1 Metronidazole +
Furazolidone+ Simethicone Tablets
Metronidazole 300 mg Furazolidone 100 mg Simethicone 25 mg
10x10’s Strip/ Blister
61.88 68.12
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the
specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
…/24
-24- (k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.315(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Ciprofloxacin+
Dexamethasone Eye/ Ear Drop
Ciprofloxacin HCl eq to Ciprofloxacin -0.3% w/v Dexamethasone-0.01 % w/v
10ml Vial with Dropper &
Carton
9.26 10.19
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
…/25
-25- (i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.316(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Prednisolone+
Methylcellulose Benzalkonium Chloride Eye Drops
Prednisolone Sodium Phosphate 1% w/v Methylcellulose (4000 Centipoises) -0.2 % w/v Benzalkonium Chloride Solution-0.02% w/v (as preservative)
5ml Vial with Dropper
13.78 15.17
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
…/26
-26- (f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.317(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. No.
Name of the Formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each ml contains 1 Ofloxacin+
Dexamethasone+ Hydroxy Propyl Methyl Cellulose+ Benzalkonium Chloride Eye Drops
Ofloxacin - 0.3% w/v Dexamethasone - 0.05% w/v Hydroxy Propyl Methyl Cellulose- 0.25 % w/v Benzalkonium Chloride - 0.02% w/v
5ml Vial with
Dropper & Carton
8.12 8.94
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for
the specified pack and packs of similar strength, and companies cannot claim exemption on any ground
therefrom, unless specifically permitted by the Government/NPPA through an order. …/27
-27- (b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet and capsule packed in strip/blister. (d) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(e) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(f) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(g) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (h) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(i) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(j) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(k) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand automatically withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.318(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1054(E), dated 11th July, 2007, in so far as it relates to formulation packs mentioned in the table-I below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/28
-28-
Table-I: Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains
“1. Trimethoprim+ Trimethoprim 40 mg 50mlBottle 11.12 12.24” Sulphamethoxazole Sulphamethoxazole -200 mg with M. Cup Suspension
*Subject to actual payment of Government levies/taxes, as applicable. Note: (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table-II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 6.32 6.96 20 7.52 8.28 30 8.76 9.64 50 11.12 12.24 100 17.50 19.27 150 24.44 26.91 200 30.28 33.34 250 36.26 39.92 500 67.18. 73.96
For pack size other than pack size given in column (1) of the table-II deduct @ Rs. 0.10746 per ml. from the ceiling
price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table-I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
…/29
-29- (j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.319(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 548(E), dated 24th March, 2008, in so far as it relates to formulation packs mentioned in the table-I below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I: Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains “1. Sulphadoxine+ Sulphadoxine -250 mg 10ml Glass 7.92 8.72” Pyrimethamine Pyrimethamine -12.5 mg Bottle with Suspension M. Cup & Carton
*Subject to actual payment of Government levies/taxes, as applicable. Note: (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table-II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 7.92 8.72 20 9.82 10.81 30 11.78 12.97 50 15.84 17.44 100 26.04 28.67 150 37.50 41.28 200 46.86 51.59 250 56.36 62.05 500 106.18 116.89
For pack size other than pack size given in column (1) of the table-II deduct @ Rs. 0.17786 per ml. from the ceiling
price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from
price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/
marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in
column (5) and equivalent MRP notified in column (6) of the table-I. …/30
-30- (b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.320(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 636(E), dated 24th March, 2008, in so far as it relates to formulation packs mentioned in the table-I below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/31
-31-
Table-I: Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains “1. Pyrantel Pamoate Pyrantel Pamoate eq. to 10ml Glass Bottle 10.38 11.43” Suspension Pyrantel - 250 mg with M. Cup & Carton
*Subject to actual payment of Government levies/taxes, as applicable. Note: (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table-II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 10.38 11.43 20 14.74 16.23 30 19.16 21.09 50 28.14 30.98 100 50.64 55.75 150 74.40 81.91 200 96.06 105.75 250 117.86 129.75 500 229.18 252.30
For pack size other than pack size given in column (1) of the table-II deduct @ Rs. 0.42386 per ml. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/ marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table-I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
…/32
-32- (j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.321(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 430(E), dated 23rd March, 2007, in so far as it relates to formulation packs mentioned in the table-I below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I: Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains “1. Chloroquine Chloroquine Phosphate 60ml Glass 15.00 15.60” Suspension eq to 50 mg Chloroquine base Bottle with M. Cup & Carton
*Subject to actual payment of Government levies/taxes, as applicable. Note: (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table-II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 7.22 7.95 20 8.40 9.25 30 9.66 10.63 50 12.30 13.54 100 18.98 20.90 150 26.90 29.61 200 32.72 36.02 250 38.70 42.60 500 70.84 77.99
For pack size other than pack size given in column (1) of the table-II deduct @ Rs. 0.0995 per ml. from the ceiling
price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from
price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by
manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to
price notified in column (5) and equivalent MRP notified in column (6) of the table-I. …/33
-33- (b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/ marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.322(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 744(E), dated 19th May, 2006, in so far as it relates to formulation packs mentioned in the table-I below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
…/34
-34-
Table-I: Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains
“1. Lincomycin Lincomycin HCl eq. to 60 ml Glass 23.08 25.41” Suspension Lincomycin base - 125 mg Bottle with m cup & carton
*Subject to actual payment of Government levies/taxes, as applicable. Note: (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table-II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 8.66 9.53 20 11.30 12.44 30 14.00 15.41 50 19.54 21.51 100 33.44 36.81 150 48.60 53.50 200 61.66 67.88 250 74.86 82.41 500 143.18 157.63
For pack size other than pack size given in column (1) of the table-II deduct @ Rs. 0.25186 per ml. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table-I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
…/35
-35- (j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the
table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that
formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount
along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.323(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I: Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains “1. Salbutamol + Salbutamol Sulphate eq to 60ml Bottle 12.54 13.81” Ambroxol+ Salbutamol- 0.5mg with M. Cup Guaiphensine+ Ambroxol HCL - 15mg & Carton Menthol Syrup Guaiphensine- 50mg Menthol - 1mg
*Subject to actual payment of Government levies/taxes, as applicable. Note: (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table-II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 6.92 7.62 20 7.78 8.57 30 8.74 9.62 50 10.76 11.85 100 15.58 17.15 150 22.26 24.51 200 26.52 29.20 250 30.96 34.08 500 55.36 60.95
…/36
-36-
For pack size other than pack size given in column (1) of the table-II deduct @ Rs. 0.07622 per ml. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table-I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by
the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor
of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceuticals Pricing Authority
S.O.324(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.II
…/37
-37- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP*(inclusive of
all taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains “1. Salbutamol+ Salbutamol Sulphate 1mg 100ml 12.72 14.00” Theopylline+ Theopylline -30mg Chlorpheniramine + Chlorpheniramine Maleate -1mg
Glass Bottle
Sodium Citrate+ Sodium Citrate -75mg Menthol Syrup Menthol -1mg
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 5.40 5.94 20 6.14 6.76 30 6.98 7.68 50 8.48 9.34 100 12.72 14.00 150 17.52 19.29 200 21.20 23.34 250 25.06 27.59 500 45.26 49.83
For pack size other than pack size given in column (1) of the table – II deduct @ Rs. 0.06462 per ml. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
…/38
-38- (f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.325(E) PN/106/2009/F F.No.8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each 5ml contains “1. Multivitamin Carbonyl Iron - 30 mg 200ml 27.82 30.63” Suspension Vitamin B12 - 5 mcg Bottle Folic Acid - 500 mcg Zinc Gluconate - 6 mcg Vitamin E Acetate - 10 IU Selenium - 30 mcg
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:- …/39
-39-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in ml. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
10 5.72 6.30 20 6.82 7.51 30 7.98 8.79 50 10.14 11.16 100 16.02 17.64 150 22.48 24.75 200 27.82 30.63 250 33.32 36.68 500 61.78 68.01
For pack size other than pack size given in column (1) of the table – II deduct @ Rs. 0.09766 per ml. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.06 per 5 ml. shall be deducted from price so worked out for pack size between 251 to 500 ml. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.326(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II
…/40
-40- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each gm contains “1. Gentamycin+ Gentamycin Sulphate-0.2% w/w 10 gm 10.74 11.82” Fluocinolone Fluocinolone Acetonide-0.1 %w/w Tube Acetonide+ Miconazole Nitrate -2.0% w/w Miconazole+ Zinc Sulphate+
Zinc Sulphate - 2.5% w/w (Preservatives)
Methyl Paraben Methyl Paraben - 0.05% w/w Cream/Ointment
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table - II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in gm. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
5 7.02 7.73 10 10.74 11.82 15 14.32 15.76 20 18.00 19.82 25 21.76 23.96 30 25.46 28.03 35 29.40 32.37 50 41.16 45.31
For pack size other than pack size given in column (1) of the table – II deduct @ Rs 0.66432 per gm. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.12 per gm. shall be deducted from price so worked out for pack size between 36 to 50 gm. These prices shall be worked out by manufacturer/ marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
…/41
-41- (f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.327(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each gm contains “1. Dexamethasone+ Dexamethasone Sodium 5 gm 9.06 9.97” Polymixin B Phosphate - 1 mg Tube Sulphate+ Polymixin B Sulphate - 10000 IU Chloramphenicol Chloramphenicol - 10 mg Cream/Ointment
*Subject to actual payment of Government levies/taxes, as applicable.
…/42
-42- Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in gm. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
5 9.06 9.97 10 14.84 16.34 15 20.46 22.52 20 26.20 28.84 25 32.00 35.23 30 37.76 41.57 35 43.74 48.15 50 61.66 67.88
For pack size other than pack size given in column (1) of the table – II deduct @ Rs 1.07432 per gm. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.12 per gm. shall be deducted from price so worked out for pack size between 36 to 50 gm. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/ NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.328(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II
…/43
-43- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each gm contains “1. Genatamycin+ Genatamycin Sulphate eq to 15 gm 8.00 8.81” Flucinolone Gentamycin-0.1 % w/w Tube Acetonide+ Flucinolone Acetonide-0.01% w/w Miconazole Cream/ Miconazole Nitrate-2% w/w Ointment
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in gm. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
5 4.90 5.39 10 6.54 7.20 15 8.00 8.81 20 9.58 10.55 25 11.24 12.37 30 12.84 14.14 35 14.66 16.14 50 20.12 22.15
For pack size other than pack size given in column (1) of the table – II deduct @ Rs 0.24365 per gm. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.12 per gm. shall be deducted from price so worked out for pack size between 36 to 50 gm. These prices shall be worked out by manufacturer/ marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
…/44
-44- (f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.329(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each gm contains “1. Betamethasone+ Betamethasone 5 gm 6.66 7.33 Neomycin Cream/ Valearate - 0.12% w/w Tube Ointment Neomycin Sulphate - 0.05% w/w
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:- …/45
-45-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in gm. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
5 6.66 7.33 10 10.04 11.05 15 13.26 14.60 20 16.60 18.27 25 20.00 22.02 30 23.36 25.72 35 26.94 29.66 50 37.66 41.46
For pack size other than pack size given in column (1) of the table – II deduct @ Rs 0.59432 per gm. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.12 per gm. shall be deducted from price so worked out for pack size between 36 to 50 gm. These prices shall be worked out by manufacturer/ marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/ NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.330(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II
…/46
-46- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all taxes)
(Rs.) (1) (2) (3) (4) (5) (6)
Each gm contains “1. Ciprofloxacin+ Ciprofloxacin HCl-0.5% w/w 10 gm 6.86 7.55” Fluocinolone Fluocinolone Tube Acetonide+ Acetonide - 0.025% w/w Clotrimazole Clotrimazole - 1% w/w Cream/Ointment
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in gm. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
5 5.08 5.59 10 6.86 7.55 15 8.50 9.36 20 10.24 11.27 25 12.06 13.28 30 13.82 15.21 35 15.82 17.42 50 21.76 23.96
For pack size other than pack size given in column (1) of the table – II deduct @ Rs 0.27632 per gm. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.12 per gm. shall be deducted from price so worked out for pack size between 36 to 50 gm. These prices shall be worked out by manufacturer/marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
…/47
-47- (f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.331(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table-I below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table-I below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table-I with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table-I : Ceiling Price and Equivalent MRP for Specified Pack Size
Sl. No.
Name of the formulation
Strength Pack Size
Ceiling Price (Rs.)
Equivalent MRP* (inclusive of all
taxes) (Rs.) (1) (2) (3) (4) (5) (6)
Each gm contains “1. Gentamycin+ Gentamycin Sulphate - 1 mg 10 gm 7.92 8.72” Clobetasol+ Clobetasol Propionate - 0.50 mg Tube Miconazole+ Zinc Miconazole Nitrate - 20 mg Sulphate Cream/ Zinc Sulphate - 0.2 mg Ointment
*Subject to actual payment of Government levies/taxes, as applicable. Note : (a) In addition to packs specified in column (4) of the strength notified in column (3) of the table-I, the following
ceiling prices are fixed:- …/48
-48-
Table – II: Ceiling Prices and Equivalent MRP of other Pack Size
Volume in gm. Ceiling Price in Rs. Equivalent MRP* (inclusive of all taxes) (Rs.) Column (1) Column (2) Column (3)
5 5.60 6.17 10 7.92 8.72 15 10.08 9.78 20 12.36 11.09 25 14.70 16.18 30 17.00 18.72 35 19.52 21.49 50 27.06 29.79
For pack size other than pack size given in column (1) of the table – II deduct @ Rs 0.38232 per gm. from the ceiling price mentioned in column (2) of the nearest higher pack size, further, Rs. 0.12 per gm. shall be deducted from price so worked out for pack size between 36 to 50 gm. These prices shall be worked out by manufacturer/ marketing company and the price so worked out shall be adopted as ceiling price corresponding to price notified in column (5) and equivalent MRP notified in column (6) of the table – I.
(b) The prices fixed are the maximum retail prices (inclusive of excise duty, sales tax/VAT and local taxes if any) in
column (6) of table-I, for the specified pack and packs of similar strength, and manufacturer/marketing company cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(c) The manufacturer/marketing company may add taxes only if they have actually paid to the Government on the
price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in Form-V of DPCO, 1995.
(d) Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated
27.1.1998 for tablet(s) and capsule(s) packed in strip/blister. (e) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(f) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a
factor of 1.1009 as per the existing rates of excise duty and VAT. (i) The MRP arrived as above shall be subject to payment of Government levies/taxes as applicable and necessary
adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
(j) Any other formulation/composition not covered in the above table that has any one of the scheduled drugs in
Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.
(k) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(l) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(s) issued
prior to this date of notification stand withdrawn.
Sd/- (S.K. Bhatt)
Deputy Director S.O.332(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II
…/49
-49- -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Pfizer Products India Pvt. Ltd.
TABLE
Sl. No.
Name of the Formulation Pack Size Existing Retail Price (Rs.)
Retail Price without Excise Duty Sales
Tax/VAT and Local Tax, if any (Rs.)
Equivalent MRP* (inclusive of all taxes)(Rs.)
(1) (2) (3) (4) (5) (6) 1 Depo Medrol 40mg
Each ml contains Methyl Prednisolone Acetate - 40 mg Batch No. RO7253/ Qty. 203733
1ml Vial 52.20 60.09 62.49
2 Depo Medrol 80mg
Each ml contains Methyl Prednisolone Acetate - 80 mg Batch No. RO7260/ Qty. 160070
2ml Vial 77.73 88.90 92.46
3 Solu Medrol AOV 500mg
Each ml contains Methyl Prednisolone Sodium Succinate- 500 mg Batch No. OAWTB/ Qty. 23422
4ml Vial 596.09 685.08 712.48
4 Medrol 4mg Tablets
Each tablet contains Methyl Prednisolone Acetate - 4 mg Batch No. K032C/Qty. 14944
10x10’s Strip/Blister
324.14 359.64 374.03
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local
taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub
para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
…/50
-50- (g) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
Sd/-
(S.K. Bhatt) Deputy Director
National Pharmaceutical Pricing Authority S.O.333(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Novartis India Ltd.
TABLE
Sl. No.
Name of the Formulation Pack Size
Existing Retail
Price (Rs.)
Retail Price without Excise Duty Sales Tax /VAT and Local Tax, if any (Rs.)
Equivalent MRP*
(inclusive of all taxes) (Rs.)
(1) (2) (3) (4) (5) (6) 1 Vitalux Plus TR Tablet
Each Tablet Contains Beta carotene (Pro-vitamin A)- 10000IU Vit. C (Ascorbic Acid)- 300mg Vit. E (d-alphatocopheryl Acetate)-100IU Vit B2 (Riboflavin)- 20mg Selenium (HVP* Chelate)- 50mcg Zinc (Gluconate) -40mg Copper (HVP* Chelate) - 2mg Lutien (Supplying 176 mcg Zeaxanthin) -4mcg HVP* = Hydrylzed Vegetable Protein Qty. 10248 Packs Batch no. 1353656 - 4667 Packs Batch no. 1466067 - 4477 Packs Batch no. 1466072 - 1104 Packs
30’s Bottle
269.57 298.73 310.68
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and
local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
…/51
-51- (e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub
para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
Sd/-
(S.K. Bhatt) Deputy Director
National Pharmaceutical Pricing Authority S.O.334(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009
In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order,
1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of
Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified
in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales
Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales
Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with
the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s Win-
Medicare Pvt. Ltd.
TABLE
Sl. No.
Name of the Formulation Pack Size
Existing Retail Price (Rs.)
Retail Price without Excise Duty Sales
Tax /VAT and Local Tax, if any (Rs.)
Equivalent MRP*
(inclusive of all taxes) (Rs.)
(1) (2) (3) (4) (5) (6) 1 Daivobet Ointment
Each gm contains Calcipotriol(as Hydrate) 50mcg Betamethasone Dipropionate 0.5mg Batch no. EC7629/Qty. 20000 tubes
15gm Tube
802.36 802.36 834.45
*Subject to actual payment of Government levies/taxes, as applicable. NOTE :
(a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local
taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any
ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be
intimated to the NPPA in the Form-V of DPCO, 1995. …/52
-52- (c) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub
para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
Sd/-
(S.K. Bhatt) Deputy Director
National Pharmaceutical Pricing Authority S.O.335(E) PN/106/2009/F F.No. 8(15)/2009/D.P./NPPA-Div.-II -COPY OF- ORDER Dated 23rd January, 2009 In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Shreya Life Science.
TABLE
Sl. No.
Name of the Formulation Pack Size Existing Retail Price (Rs.)
Retail Price without
Excise Duty Sales Tax/
VAT and Local Tax, if any
(Rs.)
Equivalent MRP*
(inclusive of all taxes)
(Rs.)
(1) (2) (3) (4) (5) (6) 1 Oral Recosulin
Human Insulin Aerosol Suspension (Recombinant Human Monocomponent Insulin) Each canister contains Insulin Human - 14.44 mg Each actuation delivers: Human Insulin - 10 IU Suspended in HFA 134 an inert 10 IU Insulin as buccal spray is eq. to 1 IU of injectable regular human insulin given by s.c. route. Batch no. 8ERO702/Qty. 2500 Packs Qty. 10000 Canister Batch no. 8ERO702/Qty. 5630 packs Batch no. 8ERO803/Qty. 4370 packs Total 10000 Packs
Aerosol of 2 Canister
of 2 ml each along
with a delivery device
-- 2296.73 2388.60
…/53
-53-
(1) (2) (3) (4) (5) (6) 2 Recosulin M30 100iu/ml
Insulin Injection Isophane Ph Eur Recombinanat Human Monocomponenet Insulin Each ml contains 30/70 of Insulin Ph Eur & Isophane Human Insulin -100.IU m-Cresol USP - 1.5mg Phenol Ph Eur 0.65 mg Excipient -QS Batch no. 61011108/Qty. 25000
3 ml Cartridge
215.63 225.49 234.51
*Subject to actual payment of Government levies/taxes, as applicable. NOTE : (a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local
taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any
ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies/manufacturers may added taxes only if they have paid actually to the Government on the price
mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be
intimated to the NPPA in the Form-V of DPCO, 1995.
(c) For different packing material used or, different drug delivery systems or any other special features/forms
claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the companies
approaches NPPA for specific price approvals for its formulations.
(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite
prior approval from the competent Authority for any change in the composition of the above said formulation with
written prior intimation to the National Pharmaceutical Pricing Authority.
(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub
para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of
paragraph 14 of the Drugs (Prices Control) Order, 1995.
(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented
by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such
formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes
hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount
along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
Sd/- (S.K. Bhatt)
Deputy Director National Pharmaceutical Pricing Authority
S.O.336(E) PN/106/2009/F/F.No. 8(15)/2009/D.P./NPPA-Div.-II Issued by: Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) New Delhi
** ** **